Syed Ehtaishamul Haque
Syed Ehtaishamul Haque publishes mostly in Cardiology and Cardiovascular Medicine, Pathology and Forensic Medicine and Molecular Biology, on topics such as Chemotherapy-induced cardiotoxicity and mitigation, Chemotherapy-induced organ toxicity mitigation and Cardiac Ischemia and Reperfusion.
- World rank
- #1,115,273 of 7,710,434 ranked researchers
- Rank in India
- #16,143 of 280,097
- Works
- 82
- Citations
- 2.2k
- Citations per work
- 27.3
What does Syed Ehtaishamul Haque research?
Syed Ehtaishamul Haque's work is mostly in Medicine (29%), Biochemistry, Genetics and Molecular Biology (12%), Chemistry (6%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else4149.4%
- Health Sciences2428.7%
- Medicine2428.7%
- Life Sciences1316.3%
- Physical Sciences55.6%
- Chemistry55.6%
- 1Cardiology and Cardiovascular Medicine12% of their works
- 2Pathology and Forensic Medicine12% of their works
- 3Molecular Biology12% of their works
- 4Organic Chemistry6% of their works
- 5Pharmacology5% of their works
- 6Complementary and alternative medicine4% of their works
Research topics
- Chemotherapy-induced cardiotoxicity and mitigation
- Chemotherapy-induced organ toxicity mitigation
- Cardiac Ischemia and Reperfusion
- Cardiac Fibrosis and Remodeling
- Genomics, phytochemicals, and oxidative stress
- Drug-Induced Hepatotoxicity and Protection
- Cardiovascular Function and Risk Factors
- Medicinal Plants and Neuroprotection
Which keywords describe Syed Ehtaishamul Haque's research?
The keywords of their largest research topics: Oxidative Stress, Chemotherapy, Antioxidants, Mitochondrial Dysfunction, Myocardial Infarction, Anthracyclines, Cisplatin and Doxorubicin.
- Nrf2
- Hepatotoxicity
- Drug-Induced Liver Injury
- Centella asiatica
- Inflammatory Response
- Heart Failure
- Cardioprotection
- Doxorubicin
- Anthracyclines
- Mitochondrial Dysfunction
- Chemotherapy
- Oxidative Stress
- Antioxidants
- Myocardial Infarction
- Cisplatin
- Nephrotoxicity
- Ischemia-Reperfusion Injury
- Cardiac Remodeling
- Bacopa monnieri
- Chamber Quantification
- Echocardiography
- Keap1-Nrf2-ARE Pathway
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 22 words, with their numbers
- Oxidative Stress505 topics
- Chemotherapy282 topics
- Antioxidants192 topics
- Mitochondrial Dysfunction192 topics
- Myocardial Infarction182 topics
- Anthracyclines141 topic
- Cisplatin141 topic
- Doxorubicin141 topic
- Nephrotoxicity141 topic
- Cardioprotection121 topic
- Ischemia-Reperfusion Injury121 topic
- Heart Failure112 topics
- Cardiac Remodeling61 topic
- Inflammatory Response61 topic
- Bacopa monnieri51 topic
- Centella asiatica51 topic
- Chamber Quantification51 topic
- Drug-Induced Liver Injury51 topic
- Echocardiography51 topic
- Hepatotoxicity51 topic
- Keap1-Nrf2-ARE Pathway51 topic
- Nrf251 topic
Where does Syed Ehtaishamul Haque work?
Syed Ehtaishamul Haque's main affiliation in the publication record is Jamia Hamdard, India.
How many publications and citations does Syed Ehtaishamul Haque have?
OpenAlex counts 82 works and 2,242 citations for Syed Ehtaishamul Haque, an h-index of 25, ranking #1,115,273 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Syed Ehtaishamul Haque. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.